EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effect of protease inhibitors on the intraerythrocytic development of Babesia microti and Babesia duncani , the causative agents of human babesiosis

Temitope Aderanti, Jordan M Marshall, Jose Thekkiniath iD

Journal of Eukaryotic Microbiology · 2025

DOI: 10.1111/jeu.13064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Eukaryotic Microbiology, 2025. Verfasst von Temitope Aderanti und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Purdue University Fort Wayne, Fort Wayne, Indiana, USA. Hauptthemen laut MEDLINE: Babesiosis, Babesia, Babesia microti, Protease Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human babesiosis is a malaria‐like, tick‐borne infectious disease with a global distribution. Babesiosis is caused by intraerythrocytic, apicomplexan parasites of the genus Babesia. In the United States, human babesiosis is caused by Babesia microti and Babesia duncani. Current treatment for babesiosis includes either the combination of atovaquone and azithromycin or the combination of clindamycin and quinine. However, the side effects of these agents and the resistance posed by these parasites call for alternative approaches for treating human babesiosis. Proteases play several roles in the context of parasitic lifestyle and regulate basic biological processes including cell death, cell progression, and cell migration. Using the SYBR Green‐1 assay, we screened a protease inhibitor library that consisted of 160 compounds against B. duncani in vitro and identified 13 preliminary hits. Dose response assays of hit compounds against B. duncani and B. microti under in vitro conditions identified five effective inhibitors against parasite growth. Of these compounds, we chose ixazomib, a proteasome inhibitor as a potential drug for animal studies based on its lower IC 50 and a higher therapeutic index in comparison with other compounds. Our results suggest that Babesia proteasome may be an important drug target and that developing this class of drugs may be important to combat human babesiosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BabesiosisBabesiaBabesia microtiProtease InhibitorsErythrocytesAntiprotozoal AgentsHumansAnimals

Stichwörter der Autor:innen

drug developmentgrowth inhibitionhuman babesiosisin vitro cultureparasiteproliferation

Substanzen

Protease InhibitorsAntiprotozoal Agents

Autor:innen und Institutionen

  • Department of Biological Sciences, Purdue University Fort Wayne, Fort Wayne, Indiana, USA.

ORCID-Profile: Jose Thekkiniath

Zitieren

APA

Aderanti, T., Marshall, J. M., & Thekkiniath, J. (2025). Effect of protease inhibitors on the intraerythrocytic development of Babesia microti and Babesia duncani , the causative agents of human babesiosis. Journal of Eukaryotic Microbiology. https://doi.org/10.1111/jeu.13064

Vancouver

Aderanti T, Marshall JM, Thekkiniath J. Effect of protease inhibitors on the intraerythrocytic development of Babesia microti and Babesia duncani , the causative agents of human babesiosis. Journal of Eukaryotic Microbiology. 2025. doi:10.1111/jeu.13064

BibTeX
@article{Aderanti2025,
  author = {Aderanti, Temitope and Marshall, Jordan M and Thekkiniath, Jose},
  title = {Effect of protease inhibitors on the intraerythrocytic development of Babesia microti and Babesia duncani , the causative agents of human babesiosis},
  journal = {Journal of Eukaryotic Microbiology},
  year = {2025},
  doi = {10.1111/jeu.13064}
}
Kostenlos starten →